 Products |
|
| No.： | CPTA011 |
| Products： | Posaconazole |
| Synonyms： | 4-(4-(4-(4-(((3R,5R)-5-(3,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one |
| Cas No.： | 171228-49-2 |
| Molecular Formula： | C37H42F2N8O4 |
| Molecular Weight： | 700.78 |
| Assay： | ＞99.7% |
| Usage： | broad-spectrum antibiotic |
| Molecular Structure： |  |
| Posaconazole (posaconazole) is a derivative of the itraconazole, listed in 2007, the second generation of the three azole antifungal drugs. Broad antibacterial spectrum, for candida, histoplasma capsulatum and plug, sickle spore bacteria, bipolar bacteria zygomycete fungi bacteria and yeast. Including resistance to fluconazole than white beads strains, cryptococcus neoformans and aspergillus has a strong inhibitory activity; Particularly for rare, but life-threatening fungal disease (zygomycosis, sickle disease and coccidioidomycosis, etc.) is effective. Process of the body This drug is poorly soluble in water, at present only oral suspension agent, on an empty stomach or after meal oral, respectively, in 3 ~ 4 ~ 10 h and 4 h reached peak blood drug concentration. Plasma protein binding is as high as 98.2%, mainly combined with albumin. Apparent volume of distribution, on average, as high as 1744 l, highly tissue penetration. Can through the placental barrier and is secreted in the breast milk. Clinical application of This product is applicable to variety of amphotericin intolerance or refractory adult treatment of invasive fungal infections; The high risk |
|
|
